The non-significant CD58 expression in untreated CLL cases, similar to our findings with ADAM10 mRNA, suggests a potentially distinct regulatory landscape for CD58 in CLL compared to ALL (32). This evidence concerns the gene ADAM10 and acute lymphoblastic leukemia.